IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues
StockNews.AI · 426 days
High Materiality9/10
AI Summary
Preliminary Q4 revenue expected between $19.2M and $19.4M, marking record growth. Full-year 2024 revenue estimated at $73.1M to $73.3M, up 11%-12% year-over-year. Iradimed has achieved 14 consecutive quarters of record revenue. Robust backlog and increased demand expected to continue into 2025. Presentation at JPM Healthcare Conference scheduled for January 15, 2025.
Sentiment Rationale
The growth in revenue signals strong demand and performance, reminiscent of past upward price shifts after similar announcements.
Trading Thesis
Continued demand growth and record revenue suggest stable ongoing performance, impacting long-term valuations.
Market-Moving
- Preliminary Q4 revenue expected between $19.2M and $19.4M, marking record growth.
- Full-year 2024 revenue estimated at $73.1M to $73.3M, up 11%-12% year-over-year.
- Iradimed has achieved 14 consecutive quarters of record revenue.
Key Facts
- Preliminary Q4 revenue expected between $19.2M and $19.4M, marking record growth.
- Full-year 2024 revenue estimated at $73.1M to $73.3M, up 11%-12% year-over-year.
- Iradimed has achieved 14 consecutive quarters of record revenue.
- Robust backlog and increased demand expected to continue into 2025.
- Presentation at JPM Healthcare Conference scheduled for January 15, 2025.
Companies Mentioned
- IRMD (IRMD)
Earnings
The article highlights significant growth trends and future expectations, both critical for investor sentiment.